| 产品名称: | AT3B-1 |
|---|---|
| 商品货号: | TS212653 |
| Organism: | Rattus norvegicus, rat |
| Tissue: | prostate |
| Product Format: | frozen |
| Morphology: | epithelial |
| Biosafety Level: | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease: | malignant carcinoma |
| Age: | 22 months |
| Gender: | male |
| Strain: | Copenhagen |
| Applications: | AT3B-1 was derived from the AT-3 cell line. They are more resistant to vinblastine compared to controls. These cells express a multidrug (MDR) resistant phenotype. Injection of AT3 B-1 cells into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. When P-glycoprotein was blocked, the AT3 B-1 cell line demonstrated drug efflux pump activity. This cell line can be used to study chemotherapy resistance in prostate cancer. |
| Storage Conditions: | liquid nitrogen vapor phase |
| Derivation: | AT3B-1 was derived from the AT-3 cell line. AT-3 was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. When P-glycoprotein was blocked, the AT3 B-1 cell line demonstrated drug efflux pump activity. Injection of AT3 B-1 cells into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. |
| Clinical Data: | This cell line can be used to study chemotherapy resistance in prostate cancer. male |
| Comments: | AT3B-1 was derived from the AT-3 cell line. AT-3 was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. The parental cells were grown in increasing concentrations of the drug doxorubicin until the final concentration of 0.001 mM was achieved. These cells express a multidrug (MDR) resistant phenotype. They are more resistant to vinblastine compared to controls. When P-glycoprotein was blocked, the AT3 B-1 cell line demonstrated drug efflux pump activity. Injection of AT3 B-1 cells into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. This cell line can be used to study chemotherapy resistance in prostate cancer. |
| Complete Growth Medium: | RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.001 mM doxorubicin, 90%; fetal bovine serum, 10%
|
| Subculturing: | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: 1:3 to 1:8 Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation: | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions: | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Name of Depositor: | KJ Pienta |
| Deposited As: | rat |
| References: | Isaacs JT, et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986. PubMed: 3774632 Replogle-Schwab TS, et al. Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res. 17: 4535-4538, 1997. PubMed: 9494564 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |